Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

3(60.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 4(3)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02996214Phase 4Unknown

Paclitaxel Liposome for Squamous Non-Small-cell Lung Cancer Study(LIPUSU)

Role: lead

NCT02142010Not ApplicableUnknown

Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer

Role: lead

NCT01994031Phase 4Unknown

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Role: lead

NCT02142790Phase 4Unknown

Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer

Role: lead

NCT02072785Phase 3Unknown

Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia

Role: lead

All 5 trials loaded